Beta-NAP Inhibitors
Chemical inhibitors of Beta-NAP are a diverse group of compounds that specifically target and inhibit cyclin-dependent kinases (CDKs), which play a pivotal role in the regulation of cell cycle progression and neuronal differentiation processes. Alsterpaullone and Roscovitine, for example, are known to inhibit CDKs that are essential for the cell cycle, thus affecting the cellular environment in which Beta-NAP operates, particularly in the context of neuronal differentiation and neurite outgrowth. Similarly, Olomoucine's ability to inhibit CDKs can lead to a cessation of the cell cycle and related differentiation processes, thereby influencing the function of Beta-NAP in neuronal development.
The inhibitory action of Paullone on CDKs also indirectly affects the Beta-NAP pathway by halting the cell cycle progression and neuronal differentiation. AZD5438, which inhibits CDK1, 2, and 9, suppresses not just the cell cycle but also transcriptional regulation, thereby impacting the processes that Beta-NAP is involved in. Purvalanol A's inhibition of CDK1 and CDK2 has a similar effect on the cell cycle in neurons, influencing the role of Beta-NAP in these cells. Indirubin-3'-monoxime extends this inhibition to GSK-3beta, a kinase involved in neuronal cell differentiation, again affecting Beta-NAP's function. Flavopiridol's broad CDK inhibition can disrupt not only the cell cycle but also transcription elongation, processes in which Beta-NAP is implicated. Dinaciclib's strong inhibition of key CDKs, including CDK2, CDK5, CDK1, and CDK9, potentially disrupts neuronal processes critical for Beta-NAP. Furthermore, Ribociclib's selective inhibition of CDK4 and CDK6, important for the G1-S phase transition, can affect Beta-NAP's role in neuronal processes. Milciclib targets multiple CDKs and can inhibit cell cycle progression and neuronal cell proliferation, which in turn disrupts Beta-NAP's involvement in neuronal differentiation and neurite outgrowth. Lastly, SNS-032, with its specificity towards CDK2, CDK7, and CDK9, suppresses transcriptional machinery and cell cycle progression, which are critical for Beta-NAP's functions within neurons.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone inhibits Cyclin-dependent kinases (CDKs) which are essential for the cell cycle progression. As Beta-NAP is involved in neuronal differentiation and neurite outgrowth, CDK inhibition can result in the cessation of cellular processes crucial for Beta-NAP function. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine selectively inhibits CDKs, including CDK5 which is implicated in neuronal function. Inhibition of CDK5 by Roscovitine can disrupt the phosphorylation state of substrates necessary for Beta-NAP's role in neurite outgrowth and synaptic function. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is another CDK inhibitor that can disrupt the cell cycle and neuronal differentiation. Since Beta-NAP is involved in neurite extension, inhibition of CDKs by Olomoucine can inhibit the processes essential for Beta-NAP to exert its function in neuronal development. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 is an inhibitor of CDK1, 2, and 9. By inhibiting these kinases, AZD5438 can suppress the cell cycle and transcriptional regulation, thereby inhibiting the cellular environment in which Beta-NAP operates, specifically affecting neurite outgrowth and maintenance. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A inhibits CDK1 and CDK2 activity. Since Beta-NAP is associated with neuronal cell processes, inhibition of these kinases by Purvalanol A can result in the inhibition of neuronal cell cycle, which in turn affects Beta-NAP's role in these cells. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is a potent inhibitor of CDKs and GSK-3beta, both of which are implicated in neuronal cell cycle and differentiation. Inhibition of these kinases can inhibit processes necessary for Beta-NAP function in neuron development and maturation. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits several CDKs and can inhibit transcription elongation. This chemical's inhibition of CDKs can disrupt the cell cycle and other processes that are necessary for Beta-NAP's role in neuronal differentiation and function. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib strongly inhibits CDKs, particularly CDK2, CDK5, CDK1, and CDK9, which are involved in cell cycle progression and transcriptional regulation. Inhibition of these kinases can disrupt neuronal processes that are critical for the function of Beta-NAP. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4 and CDK6, which are important in the G1-S phase transition. As Beta-NAP is involved in neuronal processes, inhibition of these CDKs by Ribociclib can disrupt the cellular environment necessary for Beta-NAP's function in neurons. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib targets multiple CDKs and can inhibit cell cycle progression and neuronal cell proliferation. This inhibition can disrupt the cellular processes that Beta-NAP is involved in, particularly in neuronal differentiation and neurite outgrowth. | ||||||